Pharmamarketeer

US FDA approves Novartis’ Beovu for wet age─related macular degeneration treatment

Novartis, a leading global medicines company, announced that the US Food and Drug Administration (FDA) approved Beovu (brolucizumab) injection, also known as RTH258 for the treatment of wet age─related macular degeneration (AMD).

Medhc-fases-banner
Advertentie(s)